bioRxiv Science⌕ Search

Biology subjects

Raybould, M. I. J.

Publications and source records attributed to Raybould, M. I. J..

15 recordsLinked to original sources

Modelling antibody structures at the speed of language

Protein structure prediction is currently substantially slower than obtaining sequence representations of proteins. This leads to most property prediction methods relying solely on trivial or learned sequence embeddings. However, contemporary structure prediction and sequence models are both based on Transformers, and structure prediction models often have fewer parameters, suggesting that there might be domains where accurate structure prediction adds no practical overhead to sequence-only modelling. Here, we demonstrate this can be achieved for adaptive immune proteins by introducing FlashABB, which predicts highly accurate antibody structures, and does so faster than even modestly-sized language models can embed sequences. As a component of FlashABB, we develop Flashpoint Attention, a fast and linear memory analog of Invariant Point Attention. To our knowledge, FlashABB is the first example of a model that accurately predicts protein structure faster than protein language models can generate embeddings, enabling efficient access to 3D information without the need for precomputed structures. Using FlashABB, we develop methods for predicting antibody stability and developability which can be scaled to repertoires of millions of sequences. Our results show how the computational bottleneck of protein structure prediction can be removed in some real-world cases. The code and model weights for FlashABB are available on GitHub: https://github.com/oxpig/FlashABB

molecular biology↗

Pox-AbDab: the Orthopoxvirus Antibody Database

In August 2024, the World Health Organisation declared the mpox orthopoxvirus to be a Public Health Emergency of International Concern for the second time in three years, emphasising the need for continued studies into its microbiology and potential therapeutic interventions. Here, we present the Orthopoxvirus Antibody Database (Pox-AbDab), a repository of data on antibodies known to bind or neutralise viruses from the same genus as mpox (https://opig.stats.ox.ac.uk/webapps/poxabdab). Beyond standardising and centralising the data, we highlight challenges in translating knowledge across orthopoxviruses, such as the absence of a function-based nomenclature for virion surface antigens. We also performed an exploratory analysis of the known orthopoxvirus-binding antibody landscape, highlighting their aggregate molecular properties, cross-binding/cross-neutralisation profiles, evidence for immunodominance or immune escape from their epitopes, and gaps in coverage to help orient future research.

immunology↗

STCRpy: a software suite for T cell receptor structure parsing, interaction profiling and machine learning dataset preparation

SummaryComputational methods to guide early-stage TCR drug discovery and TCR repertoire informatics currently under-utilise solved and predicted structure data. Here, we streamline use of these data through an open-source python package for high-throughput TCR structure handling and analysis (STCRpy), facilitating analyses such as TCR:peptide-MHC complex orientation calculation/scoring, root-mean-square-distance evaluation, interaction profiling, and machine learning dataset curation. Availability and implementationFreely available as a Python package at https://github.com/npqst/STCRpy. Contactdeane@stats.ox.ac.uk, raybould@stats.ox.ac.uk

immunology↗

The Observed T cell receptor Space database enables paired-chain repertoire mining, coherence analysis and language modelling

T cell activation is governed through T cell receptors (TCRs), heterodimers of two sequence-variable chains (often an alpha [] and beta [{beta}] chain) that recognise linear antigen fragments presented on the cell surfaces. Early sequencing technologies limited the study of immune repertoire TCRs to unpaired transcripts, leading to extensive analysis of {beta}-chain data alone as its greater sequence diversity suggested it should dominate antigen recognition. Over time, structural data has revealed that both and {beta} chains contribute to binding most antigens and highthroughput single-cell handling technologies have been increasingly applied to obtain samples of complete TCR variable region sequences from repertoires. Despite this, there is currently no repository dedicated to the curation of publicly available paired TCR sequence data. We have addressed this gap by creating the Observed T cell receptor Space (OTS) database, a source of consistently processed and annotated, full-length, paired-chain TCR sequencing data from 50 studies and at least 75 individuals. Currently, OTS contains 5.35M redundant (1.63M nonredundant) predominantly human TCR sequences and, based on recent data availability trends, will grow rapidly. We perform an initial analysis of OTS, leading to the identification of pairing biases, public TCRs, and distinct chain coherence patterns relative to antibodies. We also harness the data to build a publicly available paired-chain TCR language model, providing paired embedding representations and a method for residue in-filling that is conditional on the partner chain. OTS will be updated and maintained as a central community resource and is freely downloadable and available as a web application at https://opig.stats.ox.ac.uk/webapps/ots.

immunology↗

The Patent and Literature Antibody Database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures

Antibodies are key proteins of the adaptive immune system, and there exists a large body of academic literature and patents dedicated to their study and concomitant conversion into therapeutics, diagnostics, or reagents. These documents often contain extensive functional characterisations of the sets of antibodies the describe. However, leveraging these heterogeneous reports, for example to offer insights into the properties of query antibodies of interest, is currently challenging as there is no central repository through which this wide corpus can be mined by sequence or structure. Here, we present PLAbDab (the Patent and Literature Antibody Database), a self-updating repository containing over 150,000 paired antibody sequences and 3D structural models, of which over 65,000 are unique. Each entry in the database also contains the title and authors of its literature source. Here we describe the methods used to extract, filter, pair, and model the antibodies in PLAbDab, and showcase how PLAbDab can be searched by sequence, structure, or keyword. PLAbDab uses include annotating query antibodies with potential antigen information from similar entries, analysing structural models of existing antibodies to identify modifications that could improve their properties, and compiling bespoke datasets of antibody sequences/structures known to bind to a specific antigen. PLAbDab is freely available via Github (https://github.com/oxpig/PLAbDab) and as a searchable webserver (https://opig.stats.ox.ac.uk/webapps/plabdab/).

bioinformatics↗

Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling

Antibodies with lambda light chains ({lambda}-antibodies) are generally considered to be less developable than those with kappa light chains ({kappa}-antibodies), leading to substantial systematic biases in drug discovery pipelines. This has contributed to kappa dominance amongst clinical-stage therapeutics. However, the identification of increasing numbers of epitopes preferentially engaged by{lambda} -antibodies shows there is a functional cost to neglecting them as potential lead candidates during discovery campaigns. Here, we update our Therapeutic Antibody Profiler (TAP) tool to use the latest data and machine learning-based structure prediction methods, and apply this new protocol to evaluate developability risk profiles for{kappa} -antibodies and{lambda} -antibodies based on their surface physicochemical properties. We find that{lambda} -antibodies are on average at a higher risk of poor developability -- as an indication, over 40% of single-cell sequenced human{lambda} -antibodies are flagged by TAP for risk-prone patches of surface hydrophobicity (PSH), compared to around 11% of human{kappa} -antibodies. Nonetheless, a substantial proportion of natural{lambda} -antibodies are assigned more moderate risk profiles by TAP and should therefore represent more tractable candidates for therapeutic development. We also analyse the populations of high and low risk antibodies, highlighting opportunities for strategic design that TAP suggests would enrich for more developable{lambda} -based candidates. Overall, we provide context to the differing developability of{kappa} - and{lambda} -antibodies, enabling a rational approach to incorporate more diversity into the initial pool of immunotherapeutic candidates.

bioinformatics↗

Improved computational epitope profiling using structural models identifies a broader diversity of antibodies that bind the same epitope

The function of an antibody is intrinsically linked to which epitope it engages. Clonal clustering methods, based on sequence identity, are commonly used to group antibodies that will bind the same epitope. However, such methods neglect the fact that antibodies with highly diverse sequences can exhibit similar binding site geometries and engage common epitopes. In a previous study we described SPACE1, a method that structurally clustered antibodies in order to predict their epitopes. This methodology was limited by the inaccuracies and incomplete coverage of template-based modelling. It was also only benchmarked at the level of domain-consistency on one virus class. Here, we present SPACE2, which uses the latest machine learning based structure prediction technology combined with a novel clustering protocol and benchmark it on binding data that has epitope level resolution. On six diverse sets of antigen specific antibodies we demonstrate that SPACE2 accurately clusters antibodies that engage common epitopes and achieves far higher data set coverage than clonal clustering and SPACE1. Furthermore, we show that the functionally consistent structural clusters identified by SPACE2 are even more diverse in sequence, genetic lineage, and species origin than those found by SPACE1. These results reiterate that structural data improves our ability to identify antibodies that bind the same epitope, adding information to sequence-based methods, especially in data sets of antibodies from diverse sources. SPACE2 is openly available on Github (https://github.com/oxpig/SPACE2).

bioinformatics↗

Microfluidics-enabled fluorescence-activated cell sorting of single pathogen-specific antibody secreting cells for the rapid discovery of monoclonal antibodies

Monoclonal antibodies are increasingly used to prevent and treat viral infections, playing a pivotal role in pandemic response efforts. Antibody secreting cells (ASCs, plasma cells and plasmablasts) are an excellent source of high-affinity antibodies with therapeutic potential. Current methodologies to study antigen-specific ASCs either have low throughput, require expensive and labour-intensive screening or are technically demanding and therefore not accessible to the wider research community. Here, we present a straightforward technology for the rapid discovery of monoclonal antibodies from ASCs: we combine microfluidic encapsulation of single cells into an antibody capture hydrogel with antigen bait sorting by conventional flow cytometry. With our technology, we screened millions of mouse and human ASCs and obtained anti-SARS-CoV-2 monoclonal antibodies with high affinity (pM) and neutralising capacity (<100 ng/mL) in two weeks with a high hit rate (>85%). By facilitating access into the underexplored ASC compartment, we enable fast and efficient antibody discovery as well as immunological studies into the generation of protective antibodies.

immunology↗

Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies

T-cell receptor-mimetic antibodies (TCRms) targeting disease-associated peptides presented by Major Histocompatibility Complexes (pMHCs) are set to become a major new drug modality. However, we lack a general understanding of how TCRms engage pMHC targets, which is crucial for predicting their specificity and safety. Several new structures of TCRm:pMHC complexes have become available in the past year, providing sufficient initial data for a holistic analysis of TCRms as a class of pMHC binding agents. Here, we profile the complete set of TCRm:pMHC complexes against representative TCR:pMHC complexes to quantify the TCR-likeness of their pMHC engagement. We find that intrinsic molecular differences between antibodies and TCRs lead to fundamentally different roles for their heavy/light chains and Complementarity-Determining Region loops during antigen recognition. The idiotypic properties of antibodies may increase the likelihood of TCRms engaging pMHCs with less peptide selectivity than TCRs. However, the pMHC recognition features of some TCRms, including the two TCRms currently in clinical trials, can be remarkably TCR-like. The insights gained from this study will aid in the rational design and optimisation of next-generation TCRms.

immunology↗

Epitope profiling of coronavirus-binding antibodies using computational structural modelling

Identifying the epitope of an antibody is a key step in understanding its function and its potential as a therapeutic. It is well-established in the literature that sequence-based clonal clustering can identify antibodies with similar epitope complementarity. However, there is growing evidence that antibodies from markedly different lineages but with similar structures can engage the same epitope with near-identical binding modes. Here, we describe a novel computational method for epitope profiling based on structural modelling and clustering, and show how it can identify sequence-dissimilar antibodies that engage the same epitope. We start by searching for evidence of structural conservation across the latest solved SARS-CoV-2--binding antibody crystal structures. Despite the relatively small number of solved structures, we find numerous examples of sequence-diverse but structurally-similar coronavirus-binding antibodies engaging the same epitope. We therefore developed a high-throughput structural modeling and clustering method to identify functionally-similar antibodies across the set of thousands of coronavirus-binding antibody sequences in the Coronavirus Antibody Database (CoV-AbDab). In the resulting multiple-occupancy structural clusters, 92% bind to consistent domains based on CoV-AbDab metadata. Our approach functionally links antibodies with distinct genetic lineages, species origins, and coronavirus specificities. This indicates greater convergence exists in the immune responses to coronaviruses than would be suggested by sequence-based approaches. Our results show that applying structural analytics to large class-specific antibody databases will enable high confidence structure-function relationships to be drawn, yielding new opportunities to identify functional convergence hitherto missed by sequence-only analysis.

immunology↗

Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures

Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 19 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients and may be a positive indicator of disease outcome. Clonal expansion of the B cell memory response is also observed and may be the result of memory bystander effects. There was a strong convergent sequence signature across patients, and we identified 777 clonotypes convergent between at least four of the COVID-19 patients, but not present in healthy controls. A subset of the convergent clonotypes were homologous to known SARS and SARS-CoV-2 spike protein neutralising antibodies. Convergence was also demonstrated across wide geographies by comparison of data sets between patients from UK, USA and China, further validating the disease association and consistency of the stereotypical immune response even at the sequence level. These convergent clonotypes provide a resource to identify potential therapeutic and prophylactic antibodies and demonstrate the potential of BCR profiling as a tool to help understand and predict positive patient responses.

immunology↗

CoV-AbDab: the Coronavirus Antibody Database

The emergence of a novel strain of betacoronavirus, SARS-CoV-2, has led to a pandemic that has been associated with hundreds of thousands of deaths. Research is ongoing around the world to create vaccines and therapies to minimise rates of disease spread and mortality. Crucial to these efforts are molecular characterisations of neutralising antibodies to SARS-CoV-2. Such antibodies would be valuable for measuring vaccine efficacy, diagnosing exposure, and developing effective biotherapeutics. Here, we describe our new database, CoV-AbDab, which already contains data on over 380 published/patented antibodies and nanobodies known to bind to at least one betacoronavirus. This database is the first consolidation of antibodies known to bind SARS-CoV-2 and other betacoronaviruses such as SARS-CoV-1 and MERS-CoV. We supply relevant metadata such as evidence of cross-neutralisation, antibody/nanobody origin, full variable domain sequence (where available) and germline assignments, epitope region, links to relevant PDB entries, homology models, and source literature. Our preliminary analysis exemplifies a spectrum of potential applications for the database, including identifying characteristic germline usage biases in receptor-binding domain antibodies and contextualising the diagnostic value of the SARS-CoV binding CDRH3s through comparison to over 500 million antibody sequences from SARS-CoV serologically naive individuals. Community submissions are invited to ensure CoV-AbDab is efficiently updated with the growing body of data analysing SARS-CoV-2. CoV-AbDab is freely available and downloadable on our website at http://opig.stats.ox.ac.uk/webapps/coronavirus.

immunology↗

Evidence of Antibody Repertoire Functional Convergence through Public Baseline and Shared Response Structures

The antibody repertoires of different individuals ought to exhibit significant functional commonality, given that most pathogens trigger a successful immune response in most people. Sequence-based approaches have so far offered little evidence for this phenomenon. For example, a recent study estimated the number of shared ( public) antibody clonotypes in circulating baseline repertoires to be around 0.02% across ten unrelated individuals. However, to engage the same epitope, antibodies only require a similar binding site structure and the presence of key paratope interactions, which can occur even when their sequences are dissimilar. Here, we investigate functional convergence in human antibody repertoires by comparing the anti-body structures they contain. We first structurally profile base-line antibody diversity (using snapshots from 41 unrelated individuals), predicting all modellable distinct structures within each repertoire. This analysis uncovers a high (much greater than random) degree of structural commonality. For instance, around 3% of distinct structures are common to the ten most diverse individual samples ( Public Baseline structures). Our approach is the first computational method to provide support for the long-assumed levels of baseline repertoire functional commonality. We then apply the same structural profiling approach to repertoire snapshots from three individuals before and after flu vaccination, detecting a convergent structural drift indicative of recognising similar epitopes ( Public Response structures). Antibody Model Libraries derived from Public Baseline and Public Response structures represent a powerful geometric basis set of low-immunogenicity candidates exploitable for general or target-focused therapeutic antibody screening.

immunology↗

Structural Diversity of B-Cell Receptor Repertoires along the B-cell Differentiation Axis in Humans and Mice

Most current analysis tools for antibody next-generation sequencing data work with primary sequence descriptors, leaving accompanying structural information unharnessed. We have used novel rapid methods to structurally characterize the paratopes of more than 180 million human and mouse B-cell receptor (BCR) repertoire sequences. These structurally annotated paratopes provide unprecedented insights into both the structural predetermination and dynamics of the adaptive immune response. We show that B-cell types can be distinguished based solely on these structural properties. Antigen-unexperienced BCR repertoires use the highest number and diversity of paratope structures and these patterns of naive repertoire paratope usage are highly conserved across subjects. In contrast, more differentiated B-cells are more personalized in terms of paratope structure usage. Our results establish the paratope structure differences in BCR repertoires and have applications for many fields including immunodiagnostics, phage display library generation, and \"humanness\" assessment of BCR repertoires from transgenic animals.

immunology↗

Thera-SAbDab: the Therapeutic Structural Antibody Database

The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognised by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronised with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5th August 2019) are downloadable as a single file with accompanying metadata.

immunology↗